Company intelligence / Profile preview
Windward Bio
Basel, Switzerlandwindwardbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Windward Bio is advancing WIN378, a long-acting anti-TSLP monoclonal antibody with potential to be dosed every 6 months. The company is preparing to begin Phase 2 trials in severe asthma with initial clinical readouts expected in 2026. Additional trials are planned for asthma and COPD.[6]
- Therapeutic areas
- PulmonologyImmunology
- Modalities
- Monoclonal antibodiesBispecific antibodies
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Harbour BioMedKelun-Biotech
Beyond the preview
Go deeper on Windward Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Windward Bio.